肿瘤免疫治疗是一种重要的、正在迅速发展的肿瘤治疗新模式。实体肿瘤主要由肿瘤细胞及肿瘤血管构成，单一抗肿瘤细胞、或单一抗血管生成的免疫治疗效果有限，联合免疫治疗势在必行。我们前期利用内皮细胞疫苗靶向抑制肿瘤血管生成，产生一定效果，但疫苗仍需优化；前期也采用树突状细胞（dendritic cells，DCs）疫苗抗食管鳞癌治疗，存在问题是食管癌患者标本体积小，个体化抗原获取困难。本项目拟在前期研究基础上，模拟食管鳞癌微环境诱导脐静脉内皮细胞，使其接近肿瘤血管内皮细胞特性，提高该疫苗抗肿瘤血管生成的靶向性；同时，构建人食管鳞癌PDX（patient-derived xenograft，PDX）模型，利用SCID小鼠体内扩增患者食管鳞癌组织细胞，制备个体化肿瘤细胞与DCs的融合疫苗，靶向杀伤肿瘤细胞。两种疫苗联合应用产生更强的抗癌效应，该策略有望成为具有良好应用前景的抗食管鳞癌免疫治疗新方案。

Tumor immunotherapy is an important, prosperous and new mode of tumor therapy. Solid tumor mainly consists of tumor cells and blood vessels. The therapeutic effect of a single anti-tumor cells or anti-angiogenesis therapy is limited. So, combined immunotherapy is imperative. Our preliminary research showed that the vaccine of endothelial cells inhibited tumor growth by suppressing tumor angiogenesis. However, this kind of vaccine still need to be optimized. We also have demonstrated that the vaccine of dendritic cells (DCs) has significant effect on anti-esophageal squamous carcinoma. However, the problem is the volum of esophageal carcinoma is quite small, therefore, it’s very difficult to get individualized antigen. Based on these preliminary researches, human umbilical vein endothelial cells (HUVECs) will be induced by tumor microenvironment of esophageal squamous carcinoma, to make the quality of HUVECs similar to tumor endothelial cell to play more important role in anti-tumor angiogenesis. Meanwhile, esophageal carcinoma cell will be amplified by PDX (patient-derived xenograft, PDX) model of SCID (severe combined immune deficiency, SCID) mice, to prepare individualized tumor cell/DCs fusion vaccine to kill tumor cells. The combination of two kinds of vaccine will kill both tumor cells and tumor vascular endothelial cells, to make powerful anti-tumor effect, which might present a good applied prospect in immunotherapy of anti-esophageal squamous carcinoma.